Two Sigma Advisers LP Has $811,000 Stake in AVEO Pharmaceuticals, Inc. (AVEO)

Two Sigma Advisers LP grew its stake in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) by 214.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 290,738 shares of the biopharmaceutical company’s stock after buying an additional 198,338 shares during the quarter. Two Sigma Advisers LP owned 0.25% of AVEO Pharmaceuticals worth $811,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Emory University acquired a new position in shares of AVEO Pharmaceuticals in the 4th quarter valued at about $1,682,000. California Public Employees Retirement System lifted its holdings in shares of AVEO Pharmaceuticals by 360.6% in the 4th quarter. California Public Employees Retirement System now owns 153,845 shares of the biopharmaceutical company’s stock valued at $429,000 after buying an additional 120,445 shares during the period. Essex Investment Management Co. LLC increased its stake in shares of AVEO Pharmaceuticals by 34.1% in the 4th quarter. Essex Investment Management Co. LLC now owns 202,004 shares of the biopharmaceutical company’s stock valued at $564,000 after purchasing an additional 51,384 shares in the last quarter. X Square Capital LLC purchased a new position in shares of AVEO Pharmaceuticals in the 4th quarter valued at about $557,000. Finally, Prosight Management LP purchased a new position in shares of AVEO Pharmaceuticals in the 4th quarter valued at about $2,951,000. 51.58% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other news, major shareholder Peter J. Barris acquired 920,976 shares of the business’s stock in a transaction on Tuesday, April 10th. The stock was bought at an average cost of $2.30 per share, for a total transaction of $2,118,244.80. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Ravi Viswanathan acquired 685,676 shares of the business’s stock in a transaction on Friday, April 6th. The shares were purchased at an average price of $2.24 per share, with a total value of $1,535,914.24. The disclosure for this purchase can be found here. 4.70% of the stock is currently owned by insiders.

Shares of AVEO Pharmaceuticals stock opened at $2.80 on Tuesday. AVEO Pharmaceuticals, Inc. has a twelve month low of $0.55 and a twelve month high of $4.24. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of -0.45.

Several equities analysts recently weighed in on the company. B. Riley restated a “buy” rating and issued a $5.00 price target on shares of AVEO Pharmaceuticals in a research note on Tuesday, January 16th. BidaskClub upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Finally, Zacks Investment Research upgraded AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. AVEO Pharmaceuticals presently has an average rating of “Hold” and an average price target of $4.05.

WARNING: This article was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/04/17/two-sigma-advisers-lp-has-811000-stake-in-aveo-pharmaceuticals-inc-aveo.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study.

Want to see what other hedge funds are holding AVEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO).

Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply